Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01219673 · FLOW

Participant flow

Symptom Burden in Head and Neck Cancer · Source last updated 2015-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Placebo by mouth 2 times every day. Placebo: 1 by mouth twice a day.
    id
    FG000
    title
    Placebo
  2. description
    Armodafinil 150 mg by mouth once a day. Armodafinil: 150 mg by mouth once a day.
    id
    FG001
    title
    Armodafinil
  3. description
    Minocycline 100 mg by muth two times a day. Minocycline: 100 mg by mouth twice a day.
    id
    FG002
    title
    Minocycline
  4. description
    Bupropion 100 mg by mouth two times a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG003
    title
    Bupropion
  5. description
    Armodafinil 150 mg by mouth once a day. Minocycline 100 mg by mouth two times a day. Armodafinil: 150 mg by mouth once a day. Minocycline: 100 mg by mouth twice a day.
    id
    FG004
    title
    Armodafinil + Minocycline
  6. description
    Armodafinil 150 mg by mouth once a day. Bupropion 100 mg by mouth two times a day. Armodafinil: 150 mg by mouth once a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG005
    title
    Armodafinil + Bupropion
  7. description
    Minocycline 100 mg by muth two times a day. Bupropion 100 mg by mouth two times a day. Minocycline: 100 mg by mouth twice a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG006
    title
    Minocycline + Bupropion
  8. description
    Armodafinil 150 mg by mouth once a day. Minocycline 100 mg by muth two times a day. Bupropion 100 mg by mouth two times a day. Armodafinil: 150 mg by mouth once a day. Minocycline: 100 mg by mouth twice a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG007
    title
    Armodafinil + Minocycline + Bupropion
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Due to study design changes and restrictive eligibility criteria, study enrollment was low therefore study terminated early with only one participant enrolled.
recruitment Details
Recruitment Period: March 21, 2013 to June 25, 2013. All recruitment occurred at The University of Texas (UT) MD Anderson Cancer Center.
Complete source fields
groups
  1. description
    Placebo by mouth 2 times every day. Placebo: 1 by mouth twice a day.
    id
    FG000
    title
    Placebo
  2. description
    Armodafinil 150 mg by mouth once a day. Armodafinil: 150 mg by mouth once a day.
    id
    FG001
    title
    Armodafinil
  3. description
    Minocycline 100 mg by muth two times a day. Minocycline: 100 mg by mouth twice a day.
    id
    FG002
    title
    Minocycline
  4. description
    Bupropion 100 mg by mouth two times a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG003
    title
    Bupropion
  5. description
    Armodafinil 150 mg by mouth once a day. Minocycline 100 mg by mouth two times a day. Armodafinil: 150 mg by mouth once a day. Minocycline: 100 mg by mouth twice a day.
    id
    FG004
    title
    Armodafinil + Minocycline
  6. description
    Armodafinil 150 mg by mouth once a day. Bupropion 100 mg by mouth two times a day. Armodafinil: 150 mg by mouth once a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG005
    title
    Armodafinil + Bupropion
  7. description
    Minocycline 100 mg by muth two times a day. Bupropion 100 mg by mouth two times a day. Minocycline: 100 mg by mouth twice a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG006
    title
    Minocycline + Bupropion
  8. description
    Armodafinil 150 mg by mouth once a day. Minocycline 100 mg by muth two times a day. Bupropion 100 mg by mouth two times a day. Armodafinil: 150 mg by mouth once a day. Minocycline: 100 mg by mouth twice a day. Bupropion: 100 mg by mouth twice a day.
    id
    FG007
    title
    Armodafinil + Minocycline + Bupropion
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      5. group Id
        FG004
        num Subjects
        0
      6. group Id
        FG005
        num Subjects
        0
      7. group Id
        FG006
        num Subjects
        0
      8. group Id
        FG007
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Due to study design changes and restrictive eligibility criteria, study enrollment was low therefore study terminated early with only one participant enrolled.
recruitment Details
Recruitment Period: March 21, 2013 to June 25, 2013. All recruitment occurred at The University of Texas (UT) MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice